DRI Healthcare Trust (the Trust) is a Canada-based mutual fund trust. The Trust provides unitholders with differentiated exposure to the pharmaceutical and biotechnology industries through the ownership and acquisition of pharmaceutical royalties. Its products include Eylea I, Eylea II, FluMist, Natpara, Oracea, Rydapt, Spinraza, Vonjo, Xolair, Autoimmune Portfolio and others. The Trust’s therapeutic areas include ophthalmology, vaccines, oncology, endocrinology, dermatology, respiratory, rare diseases and autoimmune diseases. The Trust's products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis and Johnson & Johnson. It has over 60 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. The Trust also has a royalty interest in Zejula and Omidria. The Trust is externally managed by its manager, DRI Capital Inc.